ESCITALOPRAM IN THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER: A DOUBLE BLIND PLACEBO CONTROL TRIAL
AbstractBackground: The tolerability and efficacy for patients with obsessive-compulsive disorder(OCD) in a large, sample on Escitalopram was studied. Methods: A total of 100 adults with aconfirmed diagnosis of OCD were included. The percentage of patients with an adequate drugtrial, defined as 42 days of continuous treatment with a serotonin- reuptake inhibitor or placebo atdosages at or above established minimal effective dosages. Results: Ninety-six percent of theadults who were newly diagnosed with OCD in the index year had an adequate trial of medicationafter their first visit for OCD. By the second half of 42 days the patient who were responding tothe treatment were randomly allocated to two groups. One group received the same drug and othergroup was given placebo. The results were complied at the end of three months of each patienttreatment. No additional psychotherapy was offered to these patients during this time period.Conclusions: Despite the typically chronic course of OCD, many patients with OCD responded tothe Esciatolpram at the dosage of twenty milligram per day.Key words: Esciatolpram, Obsessive Compulsive Disorder (OCD)
Koran LM. Obsessive-compulsive and related disorders in
adults: a comprehensive clinical guide. Cambridge, England:
Cambridge Univ. Press, 1999.
Okasha A, Lotaief F, Ashour AM, el Mahalawy N, Seif el
dawla A, el-Kholy G. The prevalence of obsessive
compulsive symptoms in a sample of Egyptian psychiatric
patients. Encephale, 2000;26:1–10.
Rasmussen SA, Eisen JL. The epidemiology and clinical
features of obsessive-compulsive disorder. Psychiatr Clin
North Am. 1992;15:743–58.
Perugi G, Akiskal HS, Gemignani A, Pfanner C, Presta S,
Milanfranchi A, et al. Episodic course in obsessivecompulsive disorder. Eur Arch Psychiatry Clin Neurosci.
Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug
treatment of obsessive-compulsive disorder (OCD): longterm trial with clomipramine and selective serotonin reuptake
inhibitors (SSRIs). Psychopharmacol Bull. 1996;32:167–73.
American Psychiatric Association. Diagnostic and statistical
manual of mental disorders, fourth edition (DSM-IV).
Washington, DC: American Psychiatric Press, 1994.
Rahman NK, Zafar S, Translation and standardization of
Padua Inventory for obsessive compulsive disorder.
Unpublished manuscript, Center for clinical Psychology,
University of the Punjab, Lahore, 1989.
Greist JH, Jefferson JW, Kobak KA Katzelnick DJ, Serlin
RC. Efficacy and tolerability of serotonin transport inhibitors
in obsessive-compulsive disorder. Arch Gen Psychiatry.
March JS, Frances A, Carpenter D, Kahn DA. eds. The expert
consensus guideline series: treatment of obsessive-compulsive
disorder. J Clin Psychiatry. 1997;58(Suppl 4):1–72.
Koran L, McElroy SL, Davidson JR Rasmussen SA,
Hollander E, Jenike MA. Fluvoxamine versus clomipramine
for obsessive-compulsive disorder: a double- blind
comparison. J Clin Psychopharmacol. 1996;16:121–9.
J Ayub Med Coll Abbottabad 2007;19(4)
Gorman JM, Korotzar A, Su G. Efficacy and comparison of
citalopram and Escitalopram in the treatment of Major
Depressive Disordre, pooled analysis of placebo controlled
trials. CNS Spectr. 2002;7(4 Suppl 1): 40–4.
Dominguez RA, Mestre SM. Management of treatmentrefractory obsessive compulsive disorder patients. J Clin
Pallanti S, Quercioli L, Paiva RS, Koran LM, Citalopram for
treatment-resistant obsessive- compulsive disorder. Eur